Kristofer Svensson
Director of Finance/CFO at GABATHER AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Rajni Hatti-Kaul | M | 65 | 10 years | |
Christer Edlund | M | - | 11 years | |
Marie-Lois Ivarsson | M | - | 11 years | |
Peter Falk | M | - | 11 years | |
Michael Robin Witt | M | - | 10 years | |
Mohammad Ibrahim | M | 47 | 10 years | |
Claes Håkan Björnberg | M | 65 | 5 years | |
Leif Robert Nilsson | M | 72 | 5 years | |
Carl Edvard Georg Hall | M | 39 | 6 years | |
Fredrik Andersson | M | - | 4 years | |
Johan Sandin | M | 54 |
Sinfonia Biotherapeutics AB
Sinfonia Biotherapeutics AB BiotechnologyHealth Technology Sinfonia Biotherapeutics AB is a Swedish clinical stage company that develops biologics for neuropathic pain. The private company is based in Huddinge, Sweden. | - |
Christine Natasha Ryan | M | - | - | |
Robert Per Hökfelt | M | 58 | 5 years | |
Stefan Rehnmark | M | - | - | |
Anders Waas | M | 67 | 5 years | |
Austin Smith | M | - | 2 years | |
Anders Lönnberg | M | - | 3 years | |
Sjödin Fredrik | M | 50 | 3 years | |
Philip Slatis | M | - | 2 years | |
Christoph Nowak | M | 38 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Lars Christer Fedrik Fåhraeus | M | 59 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Bror Thomas Pollare | M | 71 |
Sinfonia Biotherapeutics AB
Sinfonia Biotherapeutics AB BiotechnologyHealth Technology Sinfonia Biotherapeutics AB is a Swedish clinical stage company that develops biologics for neuropathic pain. The private company is based in Huddinge, Sweden. | - |
Mats Persson | M | 61 | 2 years | |
Hans-Peter Albert Ostler | M | 53 | 2 years | |
Anna Sjöblom-Hallén | M | - | 8 years | |
Theresa Comiskey Olsen | F | 61 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Bert Roland Kari Junno | M | 58 | 3 years | |
Göran Gannedahl | M | 71 | 2 years | |
Klas Ingstorp | M | 53 | 2 years | |
Kevan Cassidy | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bengt Håkan Englund | M | 72 | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kristofer Svensson
- Personal Network